Zenas BioPharma (ZBIO) Stock Price, Quote, News & History | Benzinga

SPY777.80−0.04%QQQ741.05−0.67%BTC/USD83,466.41+2.12%DIA521.47+0.69%GLD383.50+0.35%TLT78.56+0.65%

Zenas BioPharma Inc (ZBIO) Stock Price, Quote, News & History

ZBIONASDAQ

Trade with Public

Trade with Public

$26.40

-0.86-3.15%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Dividends Compare Options Stock Report

Key Statistics

Open

-

Close

$26.40

Volume / Avg.

- / 726.78K

Day Range

- - -

52 Wk Range

13.50 - 44.60

Market Cap

$1.72B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

36

Short Interest

26.9%

Days to Cover

15.48

Recent Zenas BioPharma, Inc. News

Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session

US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results. Other stocks declining in pre-market trading.

Avi Kapoor

Alpha Buying: Insider Conviction in High-Risk Biotech

Tim Melvin

Crude Oil Surges 4%; US Consumer Sentiment Declines In March

U.S. stocks down, NASDAQ drops 1.5% on Friday. Energy shares up, consumer discretionary down. University of Michigan's Consumer Sentiment Index falls.

Avi Kapoor

Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of public offerings. Other stocks also lower.

Avi Kapoor

Why Newsmax Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Newsmax Inc (NMAX) shares rose on better-than-expected Q4 results & FY26 sales guidance. Pre-market gainers include ONCO, VSA, GMEX, IZM, GVH, BATL, U, SGML, & GLND. Losers are SLND, DTCX, TOP, SVRN, & GAUZ.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-225.97M

Investing Cash Flow (TTM)

-309.41M

Financing Cash Flow (TTM)

689.00M

Free Cash Flow (TTM)

-290.97M

Capital Expenditure (TTM)

-65.00M

Net Change in Cash (TTM)

153.61M

Analyst Trends and Forecast

1

1

May

2

1

Aug

3

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.43B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1411.06

PB Ratio (TTM)

6.96

Earnings Yield % (TTM)

-36.52%

Earnings Yield % (FWD)

-19.38%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.79

Company Debt

Total Debt

$297.02M

LT Debt

$297.02M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$196.58M

Debt to Equity

1.21

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-